tiprankstipranks
The Fly

Raymond James downgrades Third Harmonic Bio on uncertainty for only asset

Raymond James downgrades Third Harmonic Bio on uncertainty for only asset

As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18 price target on the shares after the company announced that Phase 1 healthy volunteer data for THB335 supports advancement to Phase 2, but does not support a best in class profile due to toxicity. The firm is downgrading shares based on the uncertain path forward for THB335, which it notes is the only asset in Third Harmonic’s pipeline.

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1